BMS-986020 sodium is primarily investigated for its potential therapeutic applications in treating fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). It functions as a lysophosphatidic acid receptor 1 (LPA1) antagonist, which plays a key role in the pathogenesis of fibrosis by promoting fibroblast recruitment and activation. By inhibiting LPA1, BMS-986020 sodium aims to reduce the progression of fibrosis, improve lung function, and enhance patient outcomes. Clinical trials have explored its efficacy and safety, positioning it as a promising candidate for managing fibrotic conditions. Additionally, its mechanism of action suggests potential utility in other fibrotic disorders, such as liver or kidney fibrosis, though further research is needed to confirm these applications.